Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$2.39 -0.8%	$3.52	$2.09 ▼ $5.64	$160.33M	1.54	3.19 million shs	1.23 million shs
DMAC DiaMedica Therapeutics	$4.67 -3.1%	$4.09	$3.19 ▼ $6.82	$249.14M	1.25	436,340 shs	390,287 shs
NRXP NRx Pharmaceuticals	$2.52 +2.4%	$3.10	$1.10 ▼ $6.01	$42.53M	1.59	141,741 shs	174,461 shs
OGI Organigram Global	$1.45 +2.5%	$1.40	$0.85 ▼ $2.08	$188.98M	1.45	543,081 shs	601,169 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-0.83%	-9.47%	-41.42%	-10.15%	+11.68%
DMAC DiaMedica Therapeutics	-3.11%	+13.35%	+21.30%	+24.20%	+43.69%
NRXP NRx Pharmaceuticals	+2.44%	-2.70%	-25.00%	+23.53%	+29.23%
OGI Organigram Global	+2.48%	+8.65%	+0.35%	+22.46%	-3.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.9505 of 5 stars	3.4	0.0	3.2	1.7	0.6
DMAC DiaMedica Therapeutics	1.425 of 5 stars	3.5	1.0	1.1	1.7	0.0
NRXP NRx Pharmaceuticals	2.8676 of 5 stars	3.6	5.0	1.6	0.8	0.6
OGI Organigram Global	1.2332 of 5 stars	0.0	2.0	2.3	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	322.59% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$10.75	130.19% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	1,030.95% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NRXP, OGI, DMAC, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
7/18/2025	DMAC DiaMedica Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $14.00
7/18/2025	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $11.00
7/18/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	233.83	N/A	N/A	$0.88 per share	2.72
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A
OGI Organigram Global	$117.47M	1.65	N/A	N/A	$2.07 per share	0.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	8/14/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/12/2025 (Confirmed)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.10	14.45	N/A	N/A	8.05%	-5.93%	-4.39%	8/13/2025 (Confirmed)

Latest NRXP, OGI, DMAC, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	N/A	N/A	N/A	$0.10 million	N/A
8/13/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	N/A	N/A	N/A	$68.04 million	N/A
8/12/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.42	4.42
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
NRXP NRx Pharmaceuticals	N/A	0.22	0.22
OGI Organigram Global	N/A	3.42	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
DMAC DiaMedica Therapeutics	10.12%
NRXP NRx Pharmaceuticals	4.27%
OGI Organigram Global	34.63%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
DMAC DiaMedica Therapeutics	7.30%
NRXP NRx Pharmaceuticals	19.00%
OGI Organigram Global	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
DMAC DiaMedica Therapeutics	20	51.69 million	47.92 million	Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable
OGI Organigram Global	860	134.03 million	133.91 million	Optionable

NRXP, OGI, DMAC, and CRDF Headlines

Recent News About These Companies

Organigram Global (OGI) to Release Quarterly Earnings on Wednesday

August 6 at 4:39 AM | marketbeat.com

Organigram Global (NASDAQ:OGI) Trading Up 3.8% - Should You Buy?

August 5, 2025 | marketbeat.com

Organigram Global Inc. (OGI) Expands Into U.S. THC Beverage Market Across 25 States

August 2, 2025 | msn.com

Organigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025

August 1, 2025 | financialpost.comF

Organigram Global Inc. (OGI) Stock Price Today - WSJ

July 15, 2025 | wsj.com

Shareholders in Organigram Global (TSE:OGI) are in the red if they invested five years ago

July 9, 2025 | finance.yahoo.com

Organigram Expands U.S. Presence with Hemp-Derived THC Beverage Launch

July 8, 2025 | tipranks.com

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | financialpost.comF

Organigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage Portfolio

July 8, 2025 | businesswire.com

OGI Organigram Global Inc. - Seeking Alpha

June 29, 2025 | seekingalpha.com

June 2025 Watchlist: Best Canadian Cannabis Stocks for Growth

May 31, 2025 | marijuanastocks.comM

Earnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%

May 14, 2025 | uk.investing.com

OrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)

May 12, 2025 | zacks.com

OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates

May 12, 2025 | zacks.com

Insights Ahead: OrganiGram Holdings's Quarterly Earnings

May 9, 2025 | benzinga.com

Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export Awards

May 5, 2025 | finance.yahoo.com

Organigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export Awards

May 5, 2025 | businesswire.com

Organigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025

May 2, 2025 | businesswire.com

Organigram Global’s Products Recognized at the CNB Awards

April 24, 2025 | finance.yahoo.com

Organigram Global's Products Recognized at the CNB Awards

April 24, 2025 | businesswire.com

Organigram Global Shares Recording of its OG Investor Session

April 22, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer
By Leo Miller | July 22, 2025
View Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer
3 Cloud Build-Out Stocks Behind the AI Infrastructure Boom
By Chris Markoch | July 25, 2025
View 3 Cloud Build-Out Stocks Behind the AI Infrastructure Boom
3 Hot Tech Stocks Showing Bullish Price Action Right Now
By Thomas Hughes | July 11, 2025
View 3 Hot Tech Stocks Showing Bullish Price Action Right Now
4 Stocks Planning to Substantially Boost Buybacks After Solid Q2
By Leo Miller | July 28, 2025
View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q2
What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?
By Gabriel Osorio-Mazilli | July 23, 2025
View What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?

NRXP, OGI, DMAC, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$2.39 -0.02 (-0.83%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+1.05%)

As of 08/8/2025 07:53 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DiaMedica Therapeutics NASDAQ:DMAC

$4.67 -0.15 (-3.11%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.67 0.00 (0.00%)

As of 08/8/2025 04:10 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

NRx Pharmaceuticals NASDAQ:NRXP

$2.52 +0.06 (+2.44%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.55 +0.03 (+1.19%)

As of 08/8/2025 07:59 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Organigram Global NASDAQ:OGI

$1.44 +0.04 (+2.48%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$1.46 +0.02 (+1.31%)

As of 08/8/2025 07:55 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time